Pharmaceutical industry giants are intensifying their opposition to state laws mandating the distribution of discounted drugs to an unlimited number of pharmacies, resulting in a surge of legal challenges across the United States.
Major drug manufacturers, including Novartis AG, AstraZeneca PLC, and AbbVie Inc., along with the trade group Pharmaceutical Research and Manufacturers of America (PhRMA), have collectively filed 23 lawsuits against eight newly enacted state laws. These laws prohibit pharmaceutical companies from limiting the supply of discounted drugs to particular pharmacies under the federal 340B Drug Pricing Program.
The 340B program requires manufacturers to provide discounted drugs to qualifying health providers. However, the recent state laws aim to broaden the availability of these discounted medications, prompting pharmaceutical companies to push back strongly. This ongoing litigation underscores the tension between state-level regulations and the pharmaceutical industry’s interests.
For detailed coverage, you can refer to Bloomberg Law.